Aethlon Medical Inc
NASDAQ:AEMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aethlon Medical Inc
Net Income (Common)
Aethlon Medical Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aethlon Medical Inc
NASDAQ:AEMD
|
Net Income (Common)
-$11.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
62%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Income (Common)
$1.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$6.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2.9B
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
Aethlon Medical Inc
Glance View
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
See Also
What is Aethlon Medical Inc's Net Income (Common)?
Net Income (Common)
-11.5m
USD
Based on the financial report for Dec 31, 2025, Aethlon Medical Inc's Net Income (Common) amounts to -11.5m USD.
What is Aethlon Medical Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-10%
Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for Aethlon Medical Inc have been 5% over the past three years , -9% over the past five years , and -10% over the past ten years .
